9-(3-羟基-2-膦酰甲氧基丙基)-2,6-二氨基嘌呤 | 113852-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 9-(3-羟基-2-膦酰甲氧基丙基)-2,6-二氨基嘌呤
• 英文名称: (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine
• 英文别名: (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine；9-(3-Hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine；[(2S)-1-(2,6-diaminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
• CAS: 113852-35-0
• 化学式: C₉H₁₅N₆O₅P
• 分子量: 318.229
• InChiKey: XGTJCNSZEASLLL-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  183
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  9-(3-羟基-2-膦酰甲氧基丙基)-2,6-二氨基嘌呤 在 N,N'-二环己基-4-吗啉脒 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以71%的产率得到9-{[(5S)-2-hydroxy-2-oxido-1,4,2-dioxaphosphinan-5-yl]-methyl}-2,6-diaminopurine
  参考文献：
  名称：

  Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents

  摘要：

  9-(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) and its cyclic form were selected for further evaluation as potential drug candidates against poxvirus infections. To increase bioavailability of these compounds, synthesis of their structurally diverse ester prodrugs was carried out: alkoxyalkyl (hexadecyloxypropyl, octadecyloxyethyl, hexadecyloxyethyl), pivaloyloxymethyl (POM), 2,2,2-trifluoroethyl, butylsalicylyl, and prodrugs based on peptidomimetics. Most HPMPDAP prodrugs were synthesized in the form of monoesters is well as the corresponding cyclic phosphonate esters. The activity was evaluated not only against vaccinia virus hut also against different herpes viruses. The most potent and active prodrugs against vaccinia virus were the alkoxyalkyl ester derivatives of HPMPDAP, with 50% effective concentrations 400-600-fold lower than those of the parent compound. Prodrugs based on peptidomimetics, the 2,2,2-trifluoroethyl, the POM, and the butylsalicylyl derivatives, were able to inhibit vaccinia virus replication at 50% effective concentrations that were equivalent or similar to 10-fold lower than those observed for the parent compounds.

  DOI：

  10.1021/jm901828c
• 作为产物：
  描述：

  diisopropyl {[(1S)-2-(2,6-diamino-9H-purin-9-yl)-1-(hydroxymethyl)ethyl]oxy}methylphosphonate 在 盐酸 作用下， 以 水 为溶剂， 以77%的产率得到9-(3-羟基-2-膦酰甲氧基丙基)-2,6-二氨基嘌呤
  参考文献：
  名称：

  微波辅助 水解 的 膦酸酯 二酯：制备膦酸的有效方案

  摘要：

  一种新型高效的无环核苷膦酸酯水解方法 二酯 （或通常是任何有机膦酸酯） 膦酸已经被开发出来。这种新颖的方法使用廉价盐酸以等摩尔的量表示分子中存在的酯基的数目，因此避免使用三甲基甲硅烷基卤化物，这是用于这些类型转化的标准试剂。此外，对反应混合物进行简单，轻松的后处理即可提供非常干净的产品，且收率很高（通常为77％至93％）。所述水解的另一个优点是膦酸酯 二酯事实是可以通过反应容器中的压力变化立即监控反应过程。这种“绿色”方法也已成功用于制备否则难以合成的（膦酰基甲氧基）乙基（PME）的导数 鸟嘌呤 （PMEG）和 黄嘌呤 （PMEHx），此外，该方法还可以使用重要的新型无环核苷膦酸酯，这些膦酸酯衍生自 2-氯次黄嘌呤 和从 黄嘌呤（例如PMEX）。

  DOI：

  10.1039/c2gc35547g

文献信息

• General Method of Preparation of N-[(S)-(3-Hydroxy-2-phosphonomethoxypropyl)] Derivatives of Heterocyclic Bases
  作者：Petr Alexander、Antonín Holý

  DOI：10.1135/cccc19931151

  日期：——

  Reaction of (R)-1-O-p-toluenesulfonyl-1,2,3-propanetriol (IV) with N-trimethylacetylimidazole (II) afforded (R)-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (V) which was reacted with dimethoxymethane in the presence of phosphorus pentoxide to give (R)-2-O-methoxymethyl-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (VI). Compound VI was treated with acetic anhydride and boron trifluoride etherate and the obtained 2-acetoxy derivative VII reacted with bromotrimethylsilane to give the intermediary bromomethyl ether VIII. Compound VIII on reaction with tris(2-propyl) phosphite afforded (R)-2-O-bis(2-propyl)phosphonomethyl-1-O-p-toluenesulfonyl-3-O-trimethyacetyl-1,2,3-propanetriol (IX). Condensation of synthon IX with sodium salts of adenine, 2,6-diaminopurine, or with cytosine, 6-azacytosine or 2-chloroadenine in the presence of cesium carbonate, afforded fully protected diesters X and XIIIb which on methanolysis and reaction with bromotrimethylsilane gave N-[(S)-(3-hydroxy-2-phosphonomethoxypropyl)] derivatives of adenine (XIa), 2- chloroadenine (XIb), 2,6-diaminopurine (XIc), cytosine (XIVa) and 6-azacytosine (XIVb). In an analogous reaction, sodium salt of 4-methoxy-2-pyrimidone reacted with compound IX to give an intermediate XIIIa which on treatment with methanolic ammonia and subsequent deblocking under the same conditions also afforded the cytosine derivative XIVa. Sodium salt of 2-amino-6-chloropurine was in this way converted into the corresponding 2-aminopurine derivative XVIII. Deprotection of this compound gave 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-2-aminopurine (XIX).

  将(R)-1-O-p-甲苯磺酰基-1,2,3-丙三醇 (IV) 与N-三甲基乙酰亚咪唑 (II) 反应得到 (R)-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (V)，将其与磷五氧化物存在下与二甲氧基甲烷反应，得到 (R)-2-O-甲氧基甲基-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (VI)。化合物 VI 经过乙酸酐和三氟硼醚的处理，得到2-乙酰氧基衍生物 VII，再与溴三甲基硅烷反应得到中间体溴甲醚 VIII。化合物 VIII 与三(2-丙基)磷酸酯反应得到 (R)-2-O-双(2-丙基)磷酰甲基-1-O-p-甲苯磺酰基-3-O-三甲基乙酰基-1,2,3-丙三醇 (IX)。将合成物 IX 与腺嘌呤、2,6-二氨基嘌呤的钠盐或胞嘧啶、6-氮杂胞嘧啶或2-氯腺嘌呤在碳酸铯存在下缩合，得到完全保护的二酯物 X 和 XIIIb，经过甲醇解和与溴三甲基硅烷反应，得到腺嘌呤 (XIa)、2-氯腺嘌呤 (XIb)、2,6-二氨基嘌呤 (XIc)、胞嘧啶 (XIVa) 和 6-氮杂胞嘧啶 (XIVb) 的N-[(S)-(3-羟基-2-磷酸甲氧基丙基)]衍生物。类似地，4-甲氧基-2-吡啶酮的钠盐与化合物 IX 反应得到中间体 XIIIa，经过甲醇氨解和相同条件下的脱保护反应，也得到胞嘧啶衍生物 XIVa。2-氨基-6-氯嘌呤的钠盐以这种方式转化为相应的2-氨基嘌呤衍生物 XVIII。对这种化合物的去保护得到9-[(S)-(3-羟基-2-磷酸甲氧基丙基)]-2-氨基嘌呤 (XIX)。
• Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
  申请人：——

  公开号：US20030176392A1

  公开（公告）日：2003-09-18

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供了一种用于治疗、预防和/或预防寄主，特别是感染了爱泼斯坦-巴尔病毒（EBV）的人类的方法和组合物，包括向寄主施用有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地还包括药学上可接受的稀释剂或赋形剂。
• [EN] A PROCESS FOR THE PREPARATION OF (R)-9-[2-(PHOSPHONOMETH-OXY)PROPYL]ADENINE (PMPA)<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (R)-9-[2-(PHOSPHONOMETH-OXY)PROPYL]ADENINE (PMPA)
  申请人：ITHEMBA PHARMACEUTICALS PROPRIETARY LTD

  公开号：WO2014033688A1

  公开（公告）日：2014-03-06

  This invention relates to a process for the preparation of (R)-9-[2- (phosphonometh-oxy)propyl]adenine (PMPA). This invention also relates to the preparation of Tenofovir disoproxil fumarate (TDF), a compound which can be produced from PMPA. The claimed process comprises reacting compound (6) with compound (7) in presence of 2,2,6,6- tetramethylpiperidinylmagnesium to compound (2), which is hydrolysed to (3).

  这项发明涉及一种制备(R)-9-[2-(磷酸甲氧基)丙基]腺嘌呤（PMPA）的过程。这项发明还涉及Tenofovir disoproxil fumarate（TDF）的制备，这是一种可以从PMPA生产的化合物。所述的过程包括在2,2,6,6-四甲基哌啶基镁的存在下，将化合物（6）与化合物（7）反应，得到化合物（2），然后水解为（3）。
• MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES
  申请人：CLARK JEREMY

  公开号：US20080070861A1

  公开（公告）日：2008-03-20

  The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.

  本公开发明提供了用(2′R)-2′-脱氧-2′-氟-2′-C-甲基核苷或其药学上可接受的盐或前药治疗Flaviviridae感染的组合物和方法，包括丙型肝炎病毒、西尼罗病毒、黄热病毒和鼻病毒感染，在宿主中，包括动物，特别是人类。
• Modified fluorinated nucleoside analogues
  申请人：Clark Jeremy

  公开号：US20050009737A1

  公开（公告）日：2005-01-13

  The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.

  本公开发明提供了治疗黄热病病毒、西尼罗河病毒、肝炎C病毒、以及鼻病毒感染等黄病毒科感染的组合物和方法，包括对于动物和尤其是人类宿主，使用(2′R)-2′-脱氧-2′-氟-2′-C-甲基核苷或其药学上可接受的盐或前药。